NCT04718038View on ClinicalTrials.gov

Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

February 1, 2018

Study Completion Date

September 1, 2020

Conditions
Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Interventions
DRUG

Cetuximab combind mFOLFOX6/FOLFIRI

Cetuximab 500mg/m2 ivgtt 2h d1 ,q14d;mFOLFOX6: Oxaliplatin 85mg/m2 ivgtt 2h d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1, 5-Fu 2.4/m2 CIV 46h, q14d; FOLFIRI: CPT-11 180mg/m2 ivgtt 60-90mins d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1,5-Fu 2.4/m2 CIV 46-48h, q14d

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT04718038 - Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter